These documents are reprinted in EmanuelE. J., eds., Ethical and Regulatory Aspects of Clinical Research: Readings and Commentary (Baltimore: Johns Hopkins University Press, 2003): At 31, 36, and 46, respectively.
2.
Id., at 29.
3.
ChwangE., “Against the Inalienable Right to Withdraw from Research,”Bioethics22, no. 7 (2008): 370–378.
4.
SpillmanM. A.SadeR. M., “Clinical Trials of Xenotransplantation: Waiver of the Right to Withdraw from a Clinical Trial Should Be Required,”Journal of Law, Medicine & Ethics35, no. 2 (2007): 265–272.
5.
See Chwang, supra note 3, at 370.
6.
See SpillmanSade, supra note 4, at 266–268.
7.
SumnerL. W., The Moral Foundation of Rights (New York: Oxford University Press, 1987): At Chapter 2.
8.
McConnellT., Inalienable Rights: The Limits of Consent in Medicine and the Law (New York: Oxford University Press, 2000): at 5–7
9.
Id., at 8–11.
10.
This account is not stipulative. For a defense, see id., at 12–14 and 18–19. See also, Black's Law Dictionary, 8th ed. (St. Paul, MN: West Publishing, 2004): At 1348; KronmanA. T., “Paternalism and the Law of Contracts,”Yale Law Journal92, no. 5 (1983): At 775; and Rose-AckermanS., “Inalienability and the Theory of Property Rights,”Columbia Law Review85, no. 5 (1985): at 931.
11.
See McConnell, supra note 8, at 24–31.
12.
See Chwang, supra note 3, at 374.
13.
Id., at 375.
14.
Id., at 371–372.
15.
See SpillmanSade, supra note 4, at 266–267.
16.
Once a survey has been completed, one might wonder what further interests of subjects could be implicated. To cite just one possibility, subjects may have developed moral objections to the study and not wish to be complicit in any way with such a project.
17.
See SpillmanSade, supra note 4, at 269.
18.
Id., at 269. See also, FlorencioP. S.RamanathanE. D., “Legal Enforcement of Xenotransplantation Public Health Safeguards,”Journal of Law, Medicine & Ethics32, no. 1 (2004): 117–123.
19.
Id., at 270.
20.
There may be reason to doubt this, however. See GostinL. O., Public Health Law, 2nd ed. (Berkeley, CA: University of California Press, 2008): At 400–404, for a discussion of when compulsory screening and conditional screening are justified.
21.
See Chwang, supra note 3, at 371.
22.
See McConnell, supra note 8, at 83–85.
23.
Id., at 12 and 52.
24.
MenikokE.RichardsE. P., What the Doctor Didn't Say: The Hidden Truth about Medical Research (New York: Oxford University Press, 2006): At 45, arguing that a patient's waiver of the right not to sue for malpractice is not recognized by the law because it is “against public policy.”